Please ensure Javascript is enabled for purposes of website accessibility

Did the Checkpoint Inhibitor Bubble Just Burst?

By George Budwell - Updated Jul 27, 2017 at 1:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A failure in AstraZeneca's Mystic immuno-oncology drug trial sent shares of fellow cancer-fighters Agenus and Bristol-Myers Squibb tumbling Thursday.

What happened

Shares of Agenus (AGEN -1.51%), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (AZN -1.38%) Mystic trial missing its primary endpoint for progression-free survival in non-small cell lung cancer (NSCLC). Shares of Bristol-Myers Squibb's (BMY 2.33%) , which is pursuing a similar combination therapy for front-line NSCLC, also fell by as much as 6.8% in early morning trading, and were still off by 3.5% at 1:20 p.m. 

A hand pricking a bubble.

Image Source: Getty Images.

So what 

When checkpoint inhibitor antibodies work, they tend to be wildly successful, producing remarkable responses against a variety of cancers. The key concern, though, is that they only seem to work for 10% to 30% or so of patients -- which means most don't respond to these potentially game-changing therapies. Pharma companies like Agenus, AstraZeneca, and Bristol were all hoping to solve that problem by combining their checkpoint inhibitors with other anti-cancer agents.

Astra's Mystic trial, for instance, sought to tackle front-line NSCLC with a combination of its PD-L1 inhibitor Imfinzi (durvalumab), and the CTLA-4 inhibitor tremelimumab. This high-profile failure, however, suggests that combination therapies may not be a magic bullet after all.

If this proves a harbinger of trial failures to come, Agenus and Bristol could both be in for steep pullbacks. The bulk of Agenus' present value proposition is based on its diverse checkpoint inhibitor pipeline, which is expected to enable it to pursue a variety of novel combination therapies -- and perhaps give it the ability to catch up to industry leaders such as Bristol and Merck

Bristol, for its part, is hoping to find a winner in the first-line NSCLC setting with a combination remarkable similar to the one being tested in the Mystic trial. Specifically, Bristol is assessing its PD-1 inhibitor, Opdivo, in conjunction with its own CTLA-4 inhibitor, Yervoy, for this high-value indication. After an initial peek at the data earlier this year, the drugmaker decided to forgo an accelerated filing for this combo, suggesting that it may soon follow in the footsteps of Astra's failed combo. 

Now what

Astra's Mystic trial could still hit pay dirt if the combination of therapies proves to prolong overall survival compared to standard chemotherapy in the NSCLC setting. The company expects to release results on that metric from the study in the first half of next year. And Bristol is on track to release top-line data from its front-line NSCLC combination therapy study in either late 2017 or early 2018.

Taken together, these two trials could determine the fate of smaller players like Agenus that are trying to break into this highly competitive space. With the enthusiasm for checkpoint inhibitors likely to wane -- at least temporarily -- investors can expect Agenus' stock to move lower in the interim. The checkpoint inhibitor arms race, after all, might start to slow down in a big way following this latest clinical setback.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$73.80 (2.33%) $1.68
Agenus Inc. Stock Quote
Agenus Inc.
AGEN
$2.61 (-1.51%) $0.04
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.12 (-1.38%) $0.91
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$88.49 (1.24%) $1.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.